Business Development & Licensing

Join us in developing therapies to relieve suffering for people with great needs, but few options.

Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company developing life-changing treatments for patients with under-addressed disorders. We partner with companies throughout the world to bring new therapies to market to ease the burden for people living with debilitating diseases and disorders.

Expanding the Pipeline

We’re seeking to expand our pipeline. In addition to investing in our core competencies, we are interested in partnering with companies possessing compounds or platforms to develop potential precision medicine, disease modification, or curative therapies in several disease areas.

A flowchart of the pipeline in studying symptoms, precision medicine, disease modification, and curative therapies

Learn More About Our Business >

Current Partnership Portfolio

A world map of current partnership locations
Xenon Pharmaceuticals Inc.
Burnaby, Canada)

License and collaboration agreement to identify, research and develop Na channel inhibitors.

Read More >
AbbVie
Lake Bluff, Illinois

Exclusive worldwide collaboration to develop and commercialize elagolix for women’s health.

Read More >
Jnana Therapeautics
Boston, Massachusetts

Research collaboration for discovery of small molecules for target associated with CNS disorders.

Read More >
Voyager Therapeutics
Cambridge, Massachusetts

Strategic collaboration focused on the development and commercialization of Voyager Therapeutics’ gene therapy programs.

Read More >
Bial
Trofa, Portugal

Exclusive U.S. and Canadian rights to ONGENTYS.

Read More >
Sosei Heptares
Cambridge, United Kingdom

Strategic collaboration and licensing agreement to develop novel muscarinic receptor agonists.

Read More >
Idorsia LTD.
Basel, Switzerland

Acquisition and global rights to NBI-827104, a T-type Ca channel blocker, and a research collaboration to discover and identify novel T-type Ca channel blockers.

Read More >
Mitsubishi Tanabe Pharma
Osaka, Japan

Exclusive collaboration and licensing agreement for the development and commercialization of valbenazine in Japan and other select Asian markets.

Read More >
Takeda Pharmaceutical Company
Tokyo, Japan

Strategic collaboration to develop and commercialize early-to-mid stage compounds in Takeda’s psychiatry pipeline.

Read More >

AbbVie

In June 2010, Neurocrine Biosciences entered into an exclusive worldwide collaboration with AbbVie (formerly Abbott) to develop and commercialize elagolix for women’s health. Under the terms of the agreement, AbbVie is responsible for future development and commercialization.

In 2018, AbbVie received U.S. Food and Drug Administration approval for ORILISSA® (elagolix) to treat pain associated with endometriosis. In 2020, AbbVie received U.S. Food and Drug Administration approval for ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) to manage heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Under the collaboration, elagolix is also being investigated for the treatment of polycystic ovary syndrome. AbbVie is responsible for all development, marketing, and commercialization costs, and Neurocrine Biosciences is entitled to a royalty on worldwide sales of ORILISSA, ORIAHNN, and any other product containing elagolix.


Mitsubishi Tanabe Pharma

In March 2015, Neurocrine Biosciences entered into an exclusive collaboration and licensing agreement with Mitsubishi Tanabe Pharma for the development and commercialization of valbenazine in Japan and other select Asian markets.

Mitsubishi Tanabe Pharma will be responsible for all development, marketing, and commercialization costs in their territories, and Neurocrine Biosciences will be entitled to a percentage of sales by Mitsubishi Tanabe Pharma. Neurocrine Biosciences retains full commercial rights to valbenazine in North America, Europe, and other countries outside of Asia.


BIAL

Neurocrine Biosciences acquired the exclusive U.S. and Canadian rights to ONGENTYS® (opicapone) from Portela & CA, S.A. (BIAL) in 2017. In April 2020, ONGENTYS was approved by the U.S. Food and Drug Administration as an add-on treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.


Jnana Therapeautics

In October 2018, Neurocrine Biosciences entered into a research collaboration with Jnana Therapeutics to discover novel small molecule therapeutics for multiple targets associated with central nervous system (CNS) disorders. The collaboration leverages Jnana’s proprietary drug discovery platform across the solute carrier (SLC) family of transporters and Neurocrine Biosciences’ research and development expertise in CNS disorders to advance new medicines.


Voyager Therapeutics

In January 2019, Neurocrine Biosciences entered into a strategic collaboration with Voyager Therapeutics focused on the development and commercialization of Voyager Therapeautics’ gene therapy programs, including VY-FXN01 for Friedreich’s ataxia, as well as rights to two discovery programs.


Xenon Pharmaceuticals Inc.

In December 2019, Neurocrine Biosciences entered into a license and collaboration agreement with Xenon Pharmaceuticals to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 and three preclinical candidates, which it will have the exclusive right to further develop and commercialize. NBI-921352 is a potent, highly selective sodium channel inhibitor (Nav1.6) being developed to treat pediatric patients with SCN8A-DEE and other potential indications, including focal onset seizures.


Idorsia Ltd.

Neurocrine Biosciences acquired the global rights to NBI-827104 from Idorsia in May 2020. NBI-827104 is an investigational, potent, selective, orally active, brain penetrating T-type calcium channel blocker (Cav 3.1, Cav 3.2, Cav 3.3) for the potential treatment of epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS). We are also developing NBI-827104 for the potential treatment of essential tremor. The agreement also includes a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates.


Takeda Pharmaceutical Company Ltd.

In June 2020, Neurocrine Biosciences entered into a strategic collaboration with Takeda to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline. Specifically, Neurocrine Biosciences received an exclusive license for seven Takeda pipeline programs, including three clinical stage assets, which we are studying in schizophrenia, treatment-resistant depression, and anhedonia.


Sosei Heptares

In December 2021, Neurocrine Biosciences entered into a strategic collaboration and licensing agreement with Sosei Heptares to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study for the treatment of schizophrenia, dementia, and other neuropsychiatric disorders.

 

Contact us about partnership opportunities at bd@neurocrine.com